Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update Thaci D; Salgo RActa Dermatovenerol Alp Pannonica Adriat 2007[Jun]; 16 (2): 58, 60-62Atopic eczema is a chronic inflammatory skin disorder with a relapsing and remitting course. For many decades,topical corticosteroids have been the mainstay therapy for atopic dermatitis. After the introduction of calcineurin inhibitors as a corticosteroid-free alternative, there were high expectations. After the black box warning from the FDA regarding the potential theoretical risk for developing neoplasia under treatment with calcineurin inhibitors, patients and physicians became uncertain about its safety, regardless of the fact that current scientific data do not support increased concern for risk of malignancy.|*Calcineurin Inhibitors[MESH]|Administration, Topical[MESH]|Adult[MESH]|Animals[MESH]|Child[MESH]|Dermatitis, Atopic/*drug therapy[MESH]|Enzyme Inhibitors/*adverse effects/therapeutic use[MESH]|Humans[MESH]|Immunosuppressive Agents/*adverse effects/therapeutic use[MESH]|Infant[MESH]|Lymphoma/chemically induced[MESH]|Product Surveillance, Postmarketing[MESH]|Skin Neoplasms/chemically induced[MESH]|Tacrolimus/*adverse effects/*analogs & derivatives/therapeutic use[MESH] |